Does Rallies show 13F holders for MLYS?

Yes. Rallies tracks hedge fund and 13F ownership data for MLYS, including fund names, share counts, latest tracked quarter, and position changes when available.

Is MLYS research on Rallies investment advice?

No. Rallies provides research, data, and educational context for MLYS. It does not provide personalized investment advice.

MLYS (Mineralys Therapeutics, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Mineralys Therapeutics, Inc. Common Stock (MLYS) is a publicly traded Healthcare sector company. As of May 20, 2026, MLYS trades at $28.45 with a market cap of $2.18B and a P/E ratio of -12.11. MLYS moved +9.30% today. Year to date, MLYS is -20.27%; over the trailing twelve months it is +76.58%. Its 52-week range spans $8.24 to $47.65. Analyst consensus is strong buy with an average price target of $51.17. Rallies surfaces MLYS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns MLYS stock?

Hedge funds tracked by Rallies that own MLYS include Orbimed Advisors, Farallon Capital, and Centerbook Partners. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Mineralys Therapeutics, Inc. Common Stock.

MLYS Key Metrics

Key financial metrics for MLYS
Metric	Value
Price	$28.45
Market Cap	$2.18B
P/E Ratio	-12.11
EPS	$-2.29
Dividend Yield	0.00%
52-Week High	$47.65
52-Week Low	$8.24
Volume	4.05M
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-154.65M
Gross Margin	0.00%

Top Hedge Funds Holding MLYS

Orbimed Advisors holds 2.05M shares of MLYS, changed +109.39% as of Mar 31, 2026.
Farallon Capital holds 823.30K shares of MLYS, changed -75.40% as of Dec 31, 2025.
Centerbook Partners holds 89.33K shares of MLYS, changed +243.58% as of Mar 31, 2026.

Latest MLYS News

Mineralys Announces FDA Acceptance of Lorundrostat NDA, PDUFA Date Set for December 22, 2026 — May 6, 2026
Mineralys Appoints Jeffrey Munsie as CLO with 90k Options, 67.9k RSUs — Mar 24, 2026
Mineralys Reports $656.6M Cash, FDA Accepts Lorundrostat NDA with Dec 22, 2026 PDUFA — Mar 12, 2026

Recent MLYS Insider Trades

Rodman David Malcom sold 417 (~$11.49K) on May 18, 2026.
Rodman David Malcom sold 14.06K (~$401.79K) on May 13, 2026.
Rodman David Malcom sold 6.35K (~$186.35K) on May 12, 2026.

MLYS Analyst Consensus

8 analysts cover MLYS: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $51.17.

Common questions about MLYS

Who owns MLYS stock?: Hedge funds tracked by Rallies that own MLYS include Orbimed Advisors, Farallon Capital, and Centerbook Partners. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Mineralys Therapeutics, Inc. Common Stock.
Does Rallies show 13F holders for MLYS?: Yes. Rallies tracks hedge fund and 13F ownership data for MLYS, including fund names, share counts, latest tracked quarter, and position changes when available.
Is MLYS research on Rallies investment advice?: No. Rallies provides research, data, and educational context for MLYS. It does not provide personalized investment advice.